New pill shows promise against hard-to-treat lung cancer mutations

NCT ID NCT05364073

Ongoing Disease control Sponsor: ArriVent BioPharma, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 15, 2026 · Last updated May 12, 2026 · Updated 7 times

Summary

This early-stage study tests a drug called furmonertinib in 160 people with advanced lung cancer that has certain gene mutations (EGFR or HER2). The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments without success.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Allist Investigative Site

Hefei, Anhui, 230001, China
Allist Investigative Site

Beijing, Beijing Municipality, 101119, China
Allist Investigative Site

Chaoyang, Beijing Municipality, 100021, China
Allist Investigative Site

Chongqing, Chongqing Municipality, 400030, China
Allist Investigative Site

Harbin, Heilongjiang, 150081, China
Allist Investigative Site

Zhengzhou, Henan, 450003, China
Allist Investigative Site

Zhengzhou, Henan, 450052, China
Allist Investigative Site

Wuhan, Hubei, 430022, China
Allist Investigative Site

Xuzhou, Jiangsu, 221000, China
Allist Investigative Site

Nanchang, Jianxi, 330008, China
Allist Investigative Site

Changchun, Jilin, 130012, China
Allist Investigative Site

Jinan, Shandong, 250021, China
Allist Investigative Site

Jinan, Shandong, 250117, China
Allist Investigative Site

Taiyuan, Shanxi, 030013, China
ArriVent Investigative Site

Fairfax, Virginia, 22031, United States
ArriVent Investigative Site

Prescott, Arizona, 86301, United States
ArriVent Investigative Site

Sacramento, California, 95817, United States
ArriVent Investigative Site

Whittier, California, 90603, United States
ArriVent Investigative Site

Celebration, Florida, 34747, United States
ArriVent Investigative Site

Detroit, Michigan, 48202, United States
ArriVent Investigative Site

Houston, Texas, 77030, United States
ArriVent Investigative Site

Blacktown, New South Wales, 2148, Australia
ArriVent Investigative Site

St Leonards, New South Wales, 2065, Australia
ArriVent Investigative Site

Heidelberg, Victoria, 3084, Australia
ArriVent Investigative Site

Lyon, 69373, France
ArriVent Investigative Site

Medolla, 47014, Italy
ArriVent Investigative Site

Chiba, Chiba, 260-0013, Japan
ArriVent Investigative Site

Barcelona, 08035, Spain
ArriVent Investigative Site

Madrid, 28033, Spain
ArriVent Investigative Site

Madrid, 28050, Spain
ArriVent Investigative Site

Valencia, 46026, Spain
ArriVent Investigative Site

London, NW12PG, United Kingdom
Arrivent Investigative Site

Edmonton, T6G 1Z2, Canada
Arrivent Investigative Site

Toronto, M5G 2M9, Canada
Arrivent Investigative Site

Toulouse, 31059, France
Arrivent Investigative Site

Villejuif, 94800, France
Arrivent Investigative Site

Ōsaka-sayama, Osaka, 589-8511, Japan
Arrivent Investigative Site

Chūō, Tokyo, 104-0045, Japan
Arrivent Investigative Site

Koto-Ku, Tokyo, 135-8550, Japan
Arrivent Investigative Site

Amsterdam, North Holland, 1066 CX, Netherlands
Arrivent Investigative Site

Gwangju, 61469, South Korea
Arrivent Investigative Site

Seoul, 2447, South Korea

Conditions

Explore the condition pages connected to this study.

ADVANCED NON-SMALL CELL LUNG CANCER EGFR EXON 20 MUTATIONS EGFR UNCOMMON MUTATIONS, INCLUDING G719X AND S768I HER2 EXON 20 MUTATIONS METASTATIC NON-SMALL CELL LUNG CANCER NON SMALL CELL LUNG CANCER NSCLC NON-SMALL CELL LUNG CANCER (NSCLC)